Nivolumab
Acral Lentiginous Melanoma
Fred Hutchinson Cancer Centermonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Acral Lentiginous Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Yonsei University | Phase 2 | BB |
Rivoceranib Peking University Cancer Hospital & Institute | Phase 3 | B |
Nilotinib Institute of Cancer Research, United Kingdom | Phase 2 | B |
Imatinib National Cancer Institute (NCI) | Phase 2 | B |
ibi310 Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | B |
View all 29 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →